Arena Pharmaceuticals and Eisai Co. are not ready to throw in the towel with their new weight-loss drug lorcaserin, arguing that it has data from a new study that shows lorcaserin is strong enough to win approval by the Food and Drug Administration (FDA). The agency had rejected the drug’s last proposal in October questioning whether the older study, which involved diabetic patients, was too small to measure the benefit/risk profile. The agency also raised concerns about early animal trials that showed the drug caused cancerous tumors in laboratory rats. The new data shows that 37.5 percent of patients taking ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.